Papillary renal cell carcinoma – exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review
Marit Ahrens, John Haanen, Laurence Albigès, Marine Gross‐Goupil et autres
de, ch, fr, gb, es, be, nl, cz (code pays fourni par la source)